Evidence map›Paper›PMID 22968304›Full record

ArticleMolecular pharmacology2012

Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Gyöngyi N Kiss, James I Fells, Renuka Gupte, Sue-Chin Lee, Jianxiong Liu, Nóra Nusser, Keng G Lim, Ramesh M Ray, Fang-Tsyr Lin, Abby L Parrill and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. LPAFrontiers in immunology · 2019
    Article
  12. The LPACellular signalling · 2018
    Article
  13. CFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.International journal of molecular sciences · 2017
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Gyöngyi N KissDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
James I Fells
Renuka Gupte
Sue-Chin Lee
Jianxiong Liu
Nóra Nusser
Keng G Lim
Ramesh M Ray
Fang-Tsyr Lin
Abby L Parrill
Balázs Sümegi
Duane D Miller
Gabor Tigyi
Baylor College of Medicine · USUniversity of Memphis · USUniversity of Pecs · HUUniversity of Tennessee Health Science Center · US

Funding

Ligand Recognition by Phospholipid Growth Factor ReceptorsR01CA092160 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2001 to 2022
$5.9M
Analysis of Radiomitigative Cell SignalingR01AI080405 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2008 to 2012
$2.1M
Novel Radiomitigators Targeting LPA ReceptorsI01BX001187 · VA · MEMPHIS VA MEDICAL CENTER · PI TIGYI, GABOR J · 2013 to 2016
–
BLRD VA I01 BX001187NCI NIH HHS R01 CA092160NIAID NIH HHS AI80405NIAID NIH HHS R01 AI080405
6 · The paper itself

Abstract

Lysophosphatidic acid (LPA) is a highly potent endogenous lipid mediator that protects and rescues cells from programmed cell death. Earlier work identified the LPA₂ G protein-coupled receptor subtype as an important molecular target of LPA mediating antiapoptotic signaling. Here we describe the results of a virtual screen using single-reference similarity searching that yielded compounds 2-((9-oxo-9H-fluoren-2-yl)carbamoyl)benzoic acid (NSC12404), 2-((3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)propyl)thio)benzoic acid (GRI977143), 4,5-dichloro-2-((9-oxo-9H-fluoren-2-yl)carbamoyl)benzoic acid (H2L5547924), and 2-((9,10-dioxo-9,10-dihydroanthracen-2-yl)carbamoyl) benzoic acid (H2L5828102), novel nonlipid and drug-like compounds that are specific for the LPA₂ receptor subtype. We characterized the antiapoptotic action of one of these compounds, GRI977143, which was effective in reducing activation of caspases 3, 7, 8, and 9 and inhibited poly(ADP-ribose)polymerase 1 cleavage and DNA fragmentation in different extrinsic and intrinsic models of apoptosis in vitro. Furthermore, GRI977143 promoted carcinoma cell invasion of human umbilical vein endothelial cell monolayers and fibroblast proliferation. The antiapoptotic cellular signaling responses were present selectively in mouse embryonic fibroblast cells derived from LPA(1&2) double-knockout mice reconstituted with the LPA₂ receptor and were absent in vector-transduced control cells. GRI977143 was an effective stimulator of extracellular signal-regulated kinase 1/2 activation and promoted the assembly of a macromolecular signaling complex consisting of LPA₂, Na⁺ - H⁺ exchange regulatory factor 2, and thyroid receptor interacting protein 6, which has been shown previously to be a required step in LPA-induced antiapoptotic signaling. The present findings indicate that nonlipid LPA₂-specific agonists represent an excellent starting point for development of lead compounds with potential therapeutic utility for preventing the programmed cell death involved in many types of degenerative and inflammatory diseases.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntineoplastic AgentsApoptosisATPases Associated with Diverse Cellular Activitiesbcl-2-Associated X ProteinCaspasesCell LineCell Line, TumorCell ProliferationCHO CellsCricetinaeDNA FragmentationEpithelial CellsFibroblastsHumansAdaptor Proteins, Signal TransducingAntineoplastic AgentsATPases Associated with Diverse Cellular Activitiesbcl-2-Associated X ProteinCaspasesLIM Domain Proteinslysophosphatidic acidLysophospholipidsPhosphoproteinsPoly(ADP-ribose) PolymerasesProteasome Endopeptidase ComplexPSMC5 protein, humanReceptors, G-Protein-CoupledReceptors, Lysophosphatidic Acidsodium-hydrogen exchanger regulatory factorSodium-Hydrogen ExchangersTranscription Factors

Identifiers

PMID22968304
PMCPMC3502618
OpenAlexW2165379587

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.